MO

Moogene Medi Co., Ltd.

Develops nanomedicine-based drug delivery systems for treating severe diseases.

322970 | KO

Overview

Corporate Details

ISIN(s):
KR7322970005
LEI:
Country:
South Korea
Address:
경기도 하남시 미사강변중앙로7번안길 25씨동 10층(풍산동,유-테크밸리씨타워), 하남시

Description

Moogene Medi Co., Ltd. is a biotechnology company specializing in nanomedicine and the development of advanced drug delivery systems. The company focuses on its proprietary Lipid Nanoparticle (LNP) carrier system and other nano-bio technologies to safely and effectively transport a range of therapeutic agents, including genes, chemicals, and proteins. Its primary mission is to create novel therapeutics for severe and incurable diseases. The development pipeline includes gene therapies for conditions such as cancer, metabolic diseases, and androgenic alopecia, utilizing technologies like CRISPR/Cas9 gene editing. Moogene Medi operates an aseptic, GMP-grade facility, providing end-to-end support from initial research to GMP-scale production for clinical studies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-18 00:00
임상시험단계진입ㆍ종료(자율공시)
Korean 8.9 KB
2025-06-30 00:00
기업설명회(IR)개최결과
Korean 6.6 KB
2025-06-13 00:00
기업설명회(IR)개최
Korean 7.0 KB
2025-03-27 00:00
정기주주총회결과
Korean 14.7 KB
2025-03-19 00:00
감사보고서제출
Korean 9.9 KB
2025-03-19 00:00
사업보고서 (2024.12)
Korean 277.8 KB
2025-03-12 00:00
의결권대리행사권유참고서류
Korean 83.0 KB
2025-03-12 00:00
주주총회소집공고
Korean 91.4 KB
2025-03-04 00:00
주주총회소집결의
Korean 7.0 KB
2025-03-04 00:00
주주총회집중일개최사유신고
Korean 4.4 KB
2025-01-06 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB
2024-12-13 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2024-11-25 00:00
기업설명회(IR)개최결과
Korean 6.6 KB
2024-11-11 00:00
기업설명회(IR)개최
Korean 7.0 KB
2024-10-02 00:00
기타주요경영사항(자율공시)
Korean 6.9 KB

Automate Your Workflow. Get a real-time feed of all Moogene Medi Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Moogene Medi Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Moogene Medi Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.